ArticleBMC research notes2012
Decoding the informational properties of the RNA polymerase II Carboxy Terminal Domain.
Article in BMC research notes, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- The Ess1 prolyl isomerase: traffic cop of the RNA polymerase II transcription cycle.Biochimica et biophysica acta · 2014Review
- On the computational ability of the RNA polymerase II carboxy terminal domain.Communicative & integrative biology · 2014Article
- Synthetically engineered rpb1 alleles altering RNA polymerase II carboxy terminal domain phosphorylation induce discrete morphogenetic defects in Schizosaccharomyces pombe.Communicative & integrative biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe largest sub-unit of RNA polymerase II, Rpb1p, has long been known to be subject to post-translational modifications that influence various aspects of pre-mRNA processing. However, the portion of the Rpb1p molecule subject to these modifications - the carboxy-terminal domain or CTD - remains the subject of much fascination. Intriguingly, the CTD possesses a unique repetitive structure consisting of multiple repeats of the heptapeptide sequence, Y(1)S(2)P(3)T(4)S(5)P(6)S(7). While these repeats are critical for viability, they are not required for basal transcriptional activity in vitro. This suggests that - even though the CTD is not catalytically essential - it must perform other critical functions in eukaryotes. PRESENTATION OF THE HYPOTHESIS: By formally applying the long-standing mathematical principles of information theory, I explore the hypothesis that complex post-translational modifications of the CTD represent a means for the dynamic "programming" of Rpb1p and thus for the discrete modulation of the expression of specific gene subsets in eukaryotes. TESTING THE HYPOTHESIS: Empirical means for testing the informational capacity and regulatory potential of the CTD - based on simple genetic analysis in yeast model systems - are put forward and discussed. IMPLICATIONS OF THE HYPOTHESIS: These ideas imply that the controlled manipulation of CTD effectors could be used to "program" the CTD and thus to manipulate biological processes in eukaryotes in a definable manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.